Sumant Khanna

Summary

Country: India

Publications

  1. ncbi Risperidone in the treatment of acute mania: double-blind, placebo-controlled study
    Sumant Khanna
    The Psychiatric Clinic, Vasant Vihar, New Delhi, India
    Br J Psychiatry 187:229-34. 2005
  2. ncbi Response to Dr Vikram Patel
    Sumant Khanna
    The Psychiatric Clinic, 63 Paschimi Marg, Vasant Vihar, New Delhi 110 057, India
    Indian J Med Ethics 3:17-8. 2006
  3. ncbi Exploration of dimensions of psychopathology in neuroleptic-naïve patients with recent-onset schizophrenia/schizophreniform disorder
    John P John
    Department of Psychiatry, National Institute of Mental Health and Neurosciences NIMHANS, Dharmaram P O, Bangalore 560 029, India
    Psychiatry Res 121:11-20. 2003
  4. ncbi Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study
    Antony D Loebel
    Pfizer Inc, New York, NY 10018, USA
    J Clin Psychiatry 68:1333-8. 2007
  5. ncbi Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
    Anatoly B Smulevich
    National Mental Health Research Center, Moscow, Russia
    Eur Neuropsychopharmacol 15:75-84. 2005
  6. ncbi Glutamatergic dysfunction in OCD
    Kaushik Chakrabarty
    Department of Molecular Neurobiochemistry, International Graduate School of Neuroscience, Ruhr University Bochum, Bochum, Germany
    Neuropsychopharmacology 30:1735-40. 2005
  7. ncbi Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
    John M Kane
    The Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, New York, USA
    Int Clin Psychopharmacol 21:21-8. 2006

Collaborators

Detail Information

Publications7

  1. ncbi Risperidone in the treatment of acute mania: double-blind, placebo-controlled study
    Sumant Khanna
    The Psychiatric Clinic, Vasant Vihar, New Delhi, India
    Br J Psychiatry 187:229-34. 2005
    ..Severe mania is life-threatening, carries an increased risk of suicide and has a serious impact on patients and their families. Efficient and rapid control of episodes of acute mania is needed...
  2. ncbi Response to Dr Vikram Patel
    Sumant Khanna
    The Psychiatric Clinic, 63 Paschimi Marg, Vasant Vihar, New Delhi 110 057, India
    Indian J Med Ethics 3:17-8. 2006
  3. ncbi Exploration of dimensions of psychopathology in neuroleptic-naïve patients with recent-onset schizophrenia/schizophreniform disorder
    John P John
    Department of Psychiatry, National Institute of Mental Health and Neurosciences NIMHANS, Dharmaram P O, Bangalore 560 029, India
    Psychiatry Res 121:11-20. 2003
    ....
  4. ncbi Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study
    Antony D Loebel
    Pfizer Inc, New York, NY 10018, USA
    J Clin Psychiatry 68:1333-8. 2007
    ..To evaluate the efficacy, safety, and tolerability of long-term ziprasidone therapy in treatment-resistant schizophrenia...
  5. ncbi Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
    Anatoly B Smulevich
    National Mental Health Research Center, Moscow, Russia
    Eur Neuropsychopharmacol 15:75-84. 2005
    ..We conclude that risperidone monotherapy was an effective and well-tolerated treatment for bipolar mania and that efficacy was maintained over the long term...
  6. ncbi Glutamatergic dysfunction in OCD
    Kaushik Chakrabarty
    Department of Molecular Neurobiochemistry, International Graduate School of Neuroscience, Ruhr University Bochum, Bochum, Germany
    Neuropsychopharmacology 30:1735-40. 2005
    ..Our study provides preliminary evidence implicating glutamatergic excess in the pathophysiology of OCD, which needs to be further explored by studies from other centers involving larger sample sets from different age groups...
  7. ncbi Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
    John M Kane
    The Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, New York, USA
    Int Clin Psychopharmacol 21:21-8. 2006
    ..Ziprasidone was associated with a greater decrease in median prolactin levels and a lower incidence of clinically significant weight change. Neither agent caused any clinically important changes in QTc interval...